These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35369811)

  • 1. Late renal toxicity in patient with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib: A case report and literature review.
    Pham B; Kwon SM; Castillo DR; Majeed Y; Ahmad S; Hou J; Ganesan L; Mohammad S; Cao H
    J Oncol Pharm Pract; 2022 Dec; 28(8):1930-1935. PubMed ID: 35369811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
    Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M
    Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study.
    Kim M; Jin M; Jeon MJ; Kim EY; Shin DY; Lim DJ; Kim BH; Kang HC; Kim WB; Shong YK; Kim HK; Kim WG
    Thyroid; 2023 Jan; 33(1):91-99. PubMed ID: 35443825
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
    Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
    Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer.
    Herranz UA
    Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):47-53. PubMed ID: 36202606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
    Goto H; Kiyota N; Otsuki N; Imamura Y; Chayahara N; Suto H; Nagatani Y; Toyoda M; Mukohara T; Nibu KI; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
    Auris Nasus Larynx; 2018 Dec; 45(6):1249-1252. PubMed ID: 29779695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.
    Locati LD; Piovesan A; Durante C; Bregni M; Castagna MG; Zovato S; Giusti M; Ibrahim T; Puxeddu E; Fedele G; Pellegriti G; Rinaldi G; Giuffrida D; Verderame F; Bertolini F; Bergamini C; Nervo A; Grani G; Rizzati S; Morelli S; Puliafito I; Elisei R
    Eur J Cancer; 2019 Sep; 118():35-40. PubMed ID: 31299580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem.
    Nervo A; Ragni A; Gallo M; Ferraris A; Fonio P; Piovesan A; Arvat E
    Thyroid; 2020 Feb; 30(2):229-236. PubMed ID: 31854230
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful recovery from a subclavicular ulcer caused by lenvatinib for thyroid cancer: a case report.
    Kitamura M; Hayashi T; Suzuki C; Hirano S; Tateya I; Kishimoto Y; Omori K
    World J Surg Oncol; 2017 Jan; 15(1):24. PubMed ID: 28088233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival.
    De Leo S; Di Stefano M; Persani L; Fugazzola L; Colombo C
    Endocrine; 2021 May; 72(2):462-469. PubMed ID: 32885329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lenvatinib in radioiodine refractory thyroid carcinomas].
    de la Fouchardiere C
    Bull Cancer; 2016 Nov; 103(11):905-910. PubMed ID: 27817859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib.
    Platini F; Cavalieri S; Alfieri S; Bergamini C; Resteghini C; Bottiglieri A; Colombo E; Mazzeo L; Licitra L; Paolini B; Seregni E; Locati LD
    Endocrine; 2021 Sep; 73(3):641-647. PubMed ID: 33797698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.
    Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R
    Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS.
    Jasim S; Iniguez-Ariza NM; Hilger CR; Chintakuntlawar AV; Ryder MM; Morris JC; Bible KC
    Endocr Pract; 2017 Oct; 23(10):1254-1261. PubMed ID: 28816536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine-refractory differentiated thyroid cancer.
    Martínez-Trufero J
    Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):5-9. PubMed ID: 36202603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea.
    Song E; Kim M; Kim EY; Kim BH; Shin DY; Kang HC; Ahn BC; Kim WB; Shong YK; Jeon MJ; Lim DJ
    Thyroid; 2020 May; 30(5):732-738. PubMed ID: 31910091
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.
    Capdevila J; Newbold K; Licitra L; Popovtzer A; Moreso F; Zamorano J; Kreissl M; Aller J; Grande E
    Cancer Treat Rev; 2018 Sep; 69():164-176. PubMed ID: 30032061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival Predictors of Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib in Real Life.
    Marotta V; Rocco D; Crocco A; Deiana MG; Martinelli R; Di Gennaro F; Valeriani M; Valvano L; Caleo A; Pezzullo L; Faggiano A; Vitale M; Monti S
    J Clin Endocrinol Metab; 2024 Sep; 109(10):2541-2552. PubMed ID: 38501238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis.
    Oba T; Chino T; Soma A; Shimizu T; Ono M; Ito T; Kanai T; Maeno K; Ito KI
    Endocr J; 2020 Dec; 67(12):1215-1226. PubMed ID: 32814730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.